Jane Street’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Jane Street’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-4,238	Closed	-$49K	–	3322
2014 Q3	$49K	Sell	4,238 -28,856	-87%	-$441K	﹤0.01%	2424
2014 Q2	$644K	Buy	33,094 +15,970	+93%	+$282K	0.01%	1218
2014 Q1	$307K	Buy	+17,124	New	+$281K	﹤0.01%	1974
2013 Q3	–	Sell	-4,897	Closed	-$46K	–	3346
2013 Q2	$46K	Buy	+4,897	New	+$62.9K	﹤0.01%	2545

Other funds holding CASC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Jane Street's CASC Position: Q4 2014 in Review

Jane Street sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2014, closing a stake of 4,238 shares — an estimated $49K sold.

Jane Street first reported a position in CASC in Q2 2013 and held it in 4 quarters. The position peaked at $644K in Q2 2014. 86 funds tracked by Wall St. Rank hold CASC as of Q4 2014.

Jane Street reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
Jane Street sold 4,238 Cascadian Therapeutics, Inc. shares in Q4 2014, an estimated $49K.
Jane Street first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 4 quarters.
Jane Street's Cascadian Therapeutics, Inc. position peaked at $644K in Q2 2014.
86 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2014.

Based on Jane Street's 13F filing for Q4 2014, filed 17 Feb 2015.